ACR Convergence 2025

October 24-29, 2025. Chicago, Illinois.

View by Number View by Title View Sessions

Abstract Number: 1982

Bridging the Gap in Underserved Care: A Quality Improvement Initiative to Increase Pneumococcal Vaccination Rates in Immunocompromised Rheumatology Patients
Abstract Number: 1983

Documenting Transition: A Review and Intervention to Increase the Receipt of Transition Summary Letters
Abstract Number: 1984

Improving Lipid Screening Rates in Rheumatic Disease Patients: An Academic Fellowship Quality Improvement Project
Abstract Number: 1985

Identifying Gaps in Documented Contraception Counseling and Gynecology Referrals for Women on Teratogenic DMARDs: A Foundation for EMR-Based Quality Improvement
Abstract Number: 1987

Evaluating User Engagement and Real-World Impact of a PMR-Specific Digital Symptom Assessment Tool: A 12-Month Analysis of PainSpot™
Abstract Number: 1988

Advancing Vascular Assessment: Combining NIRS-VOT and Ultrasound-Based Brachial Artery Diameter for Improved Diagnostics in Healthy Controls and APS
Abstract Number: 1989

Moving Out of the Kid’s Rheum: Transitioning Young Adult Patients from Pediatric to Adult Rheumatology Practices
Abstract Number: 1990

Pilot Study: Testing the Accuracy of a Capillary Point-of-Care Device Compared to Traditional Venous Analysis for Serum Urate Measurements Among Patients with Gout
Abstract Number: 1991

Co-Use of Mycophenolate Mofetil with Pegloticase Yielded Similar Clinical Outcomes as the Co-Use of Methotrexate
Abstract Number: 1992

Tolerance of Methotrexate Coadministered with Pegloticase in Patients with Uncontrolled Gout: Findings from MIRROR RCT
Abstract Number: 1993

Risk of Cardiovascular Conditions, Bone Fractures and Mortality in Patients with Uncontrolled Gout in Comparison to Those with Controlled Gout
Abstract Number: 1994

Pharmacokinetics of Ready-to-Use Pegloticase Formulation Compared to Standard Pegloticase Dosing: Data from the AGILE Study
Abstract Number: 1995

The Prevalence of Multimorbidity and Polypharmacy Among US Adults with Gout: A General Population-Based Study
Abstract Number: 1996

Hospital Burden of Crystal-related Arthritis in Spain: a nationwide dataset of 183,001 inpatients.
Abstract Number: 1997

Bone health in patients with gout using real-world U.S. data

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].